MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41408-024-01167-8

Медицинская библиотека · Blood cancer journal · 2024

Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma.

Fortuna Gliceida Galarza, Banerjee Rahul, Savid-Frontera Constanza, Song Jinming, Morán-Segura Carlos M, Nguyen Jonathan V, Lekakis Lazaros, Fernandez-Pol Sebastian, Samraj Annie N, Naresh Kikkeri N, Vazquez-Martinez Mariola, Baz Rachid C, Spiegel Jay Y, Mikkilineni Lekha, Gubatan John M, Sidana Surbhi, de Menezes Silva Corraes Andre, Kalariya Nilesh M, Patel Krina K, Shim Kevin G, Fonseca Rafael, Ferreri Christopher, Voorhees Peter M, Richard Shambavi, Valdes Cesar Rodriguez, Sireesha Asoori, Wolf Jeffrey L, Cowan Andrew J, Sborov Douglas W, Locke Frederick L, Lin Yi, Wang Yinghong, Hansen Doris K

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and 2.2% for ciltacabtagene autoleucel). Patients developed acute-onset symptoms (typically non-bloody Grade 3+ diarrhea) with negative infectious workup beginning a median of 92.5 days (range: 22-210 days) after CAR-T therapy and a median of 85 days after cytokine release syndrome resolution. Gut biopsies uniformly demonstrated inflammation, including intra-epithelial lymphocytosis and villous blunting. In one case where CAR-specific immunofluorescence stains were available, CAR T-cell presence was confirmed within the lamina propria. Systemic corticosteroids were initiated in 10 patients (71%) a median of 25.5 days following symptom onset, with symptom improvement in 40%. Subsequent infliximab or vedolizumab led to improvement in 50% and 33% of corticosteroid-refractory patients, respectively. Five patients (36%) have died from bowel perforation or treatment-emergent sepsis. In conclusion, IEC-associated enterocolitis is a distinct but rare complication of CAR-T therapy typically beginning 1-3 months after infusion. Thorough diagnostic workup is essential, including evaluation for potential T-cell malignancies. The early use of infliximab or vedolizumab may potentially hasten symptom resolution and lower reliance on high-dose corticosteroids during the post-CAR-T period.

Для цитирования: Fortuna Gliceida Galarza, Banerjee Rahul, Savid-Frontera Constanza, Song Jinming, Morán-Segura Carlos M, Nguyen Jonathan V, Lekakis Lazaros, Fernandez-Pol Sebastian, Samraj Annie N, Naresh Kikkeri N, Vazquez-Martinez Mariola, Baz Rachid C, Spiegel Jay Y, Mikkilineni Lekha, Gubatan John M, Sidana Surbhi, de Menezes Silva Corraes Andre, Kalariya Nilesh M, Patel Krina K, Shim Kevin G, Fonseca Rafael, Ferreri Christopher, Voorhees Peter M, Richard Shambavi, Valdes Cesar Rodriguez, Sireesha Asoori, Wolf Jeffrey L, Cowan Andrew J, Sborov Douglas W, Locke Frederick L, Lin Yi, Wang Yinghong, Hansen Doris K. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma.. Blood cancer journal. 2024. DOI: 10.1038/s41408-024-01167-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.